RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

Abroad (travel likely)RecruitingPHASE4

Conditions

Acute Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact: Study coordinator (Yanmin Zhao, PhD) · zjzhaoyanmin@163.com · +8615858199217

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory

Abroad (travel likely)RecruitingPHASE1

Milwaukee, United States

Cladribine Venetoclax in Monocytic AML

Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Aurora, United States

DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

AML (Acute Myeloid Leukemia)

Abroad (travel likely)RecruitingPHASE3

Kunming, China

Haplo-Cord HSCT for AML/MDS

MDS (Myelodysplastic Syndrome) · AML (Acute Myeloid Leukemia)

Abroad (travel likely)Recruiting

Fuzhou, China · Guangzhou, China